Active ingredients: ceftriaxone
What it is used for
Ceftriaxone Alphapharm is indicated for the treatment of the following infections when caused by susceptible aerobic organisms: LOWER RESPIRATORY TRACT INFECTIONS caused by S. pneumoniae, Streptococcus species (excluding enterococci), methicillin sensitive S. aureus, H. influenzae, H. parainfluenzae, Klebsiella species (including K. pneumoniae), E. coli, E. aerogenes, Proteus mirabilis and Serratia marcescens. SKIN AND SKIN STRUCTURE INFECTIONS caused by methicillin sensitive S. aureus, methicillin sensitive S. epidermidis, Streptococcus Group B, Streptococcus Group G, Streptococcus pyogenes, Streptococcus viridans, Streptococcus species (excluding enterococci), Peptostreptococcus species, E. coli, E. cloacae, Klebsiella species (including K. pneumoniae, K. oxytoca), Proteus mirabilis, Morganella morganii, Serratia marcescens. URINARY TRACT INFECTIONS (complicated and uncomplicated) caused by E. coli, Proteus mirabilis, Proteus vulgaris, M. morganii and Klebsiella species (including K. pneumoniae). UNCOMPLICATED GONORRHOEA (cervical/urethral and rectal) caused by Neisseria gonorrhoea, including both penicillinase and non penicillinase producing strains. BACTERIAL SEPTICEMIA caused by S. pneumoniae, E. coli and H. influenzae. . BONE INFECTIONS caused by methicillin sensitive S. aureus, methicillin sensitive S. epidermidis, Streptococcus Group B, S. pneumoniae, Streptococcus species (excluding enterococci), E. coli, Enterobacter species, P. mirabilis and K. pneumoniae. JOINT INFECTIONS caused by methicillin sensitive S. aureus, S. pneumoniae, Streptococcus species (excluding enterococci), E. coli, P. mirabilis, K. pneumoniae and Enterobacter species. MENINGITIS: The initial treatment, as a single agent, of meningitis in children and immunocompetent adults when presumed or proven to be caused by Haemophilus influenzae type b, Neisseria meningitidis, Streptococcus pneumoniae or Enterobacteriaceae pending culture and sensitivity results. SURGICAL PROPHYLAXIS: The preoperative administration of a single 1 g dose of ceftriaxone may reduce the incidence of post-operative infections in patients undergoing vaginal or abdominal hysterectomy or cholecystectomy in high risk patients, surgical procedures which are classified as contaminated or potentially contaminated and patients undergoing coronary artery bypass surgery. Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted. . SUSCEPTIBILITY TESTING: Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing.
How to take it
The way to take this medicine is: Intravenous Infusion.
- Store below 25 degrees Celsius
- Protect from Light
- Store in Original Container
- Reconstituted Solution see label for shelf life
- Shelf lifetime is 24 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
A white to slightly yellow crystalline powder.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on September 1, 2020. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient ceftriaxone
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems